Open Access
Med Buccale Chir Buccale
Volume 17, Number 1, Février 2011
Page(s) 51 - 54
Section Observations cliniques / Case reports
Published online 21 February 2011
  1. Higgs DR, Thein SL, Woods WG. The molecular pathology of the thalassemias. In: The thalassemia syndromes (pp. 133-91), 4th ed. Blackwell Science, Oxford, 2001.
  2. Pootrakul P, Sirankapracha P, Hemsorach S. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in Thai patients with thalassemia. Blood 2000;96:2606-12. [PubMed]
  3. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005;353:1135-46. [CrossRef] [PubMed]
  4. Lucarelli G, Andreani M, Angelucci E. The cure of thalassemia by bone marrow transplantation.Blood Rev 2002;16:81-5.
  5. Cunningham MJ, Macklin EA, Cohen NA. Complications of β-thalassemia major in north America. Blood 2004;104:34-9. [CrossRef] [PubMed]
  6. Syndromes thalassémiques majeurs et intermédiaires: protocole national de diagnostic et de soins pour une maladie rare. Haute Autorité de Santé, Guide affection longue durée, 2008.
  7. Oliveri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61. [PubMed]
  8. Borgna-Pignatti C, Cappellini MD, de Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A. Cardiac morbidity and mortality in deferoxamine or deferiprone treated patients with thalassemia major. Blood 2006;1;107:3733-7.
  9. Emploi des vasoconstricteurs en odonto-stomatologie. Recommandations. Med Buccale Chir Buccale 2003;9;2:65-94.
  10. Prise en charge des patients sous traitements anti-vitamine K en chirurgie bucco-dentaire. Recommandations. Med Buccale Chir Buccale 2006;12:187-212.
  11. Fragatou S, Tsourveloudis I, Manesis G. Incidence of hepatocellular carcinoma in a thalassemia unit. Hemoglobin 2010;34:221-6. [CrossRef] [PubMed]
  12. Cadili A, Gara C. Complications of splenectomy. Am J Med 2008;121:371-5. [CrossRef] [PubMed]
  13. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci PM. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassemia intermedia. Br J Haematol 2000;111:467-73. [CrossRef] [PubMed]
  14. Jung S, Garret-Bernardin A, Grollemund B, Cojean N, Lutz P, Manière MC, Féki A. Manifestations dento-maxillo-faciales chez un enfant atteint d’une béta-thalassémie majeure traitée par greffe de cellules souches hématopoïétiques. A propos d’un cas. Med Buccale Chir Buccale 2006;12;3:163-70. [CrossRef] [EDP Sciences]
  15. Van Dis M, Langlais R. The thalassemias : oral manifestations and complications. Oral Surg Oral Med Oral Pathol 1986;62:229-33. [CrossRef] [PubMed]
  16. Basu S, Kumar A. Hair-on-end appearance in radiograph of skull and facial bones in a case of beta thalassemia. Br J Haematol 2008;144:807. [CrossRef] [PubMed]
  17. Chatterjee R, Bajoria R. Osteopenia-osteoporosis syndrome in patients with thalassemia: understanding of type of bone disease and response to treatment. Hemoglobin 2009;33 suppl 1:S136-8.
  18. Voskaridou E, Terpos, Spina G, Palermos J, Rahemtulla A, Loutradi ALoukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassemia. Br J Haematol 2003;123:730-7. [CrossRef] [PubMed]
  19. Leung TF, Chu Y, Lee V, Leung WK, Shing MM, Li CK. Long-term effects of pamidronate in thalassemic patients with severe bone mineral density deficits. Hemaglobin 2009;33:361-9. [CrossRef]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.